About Impulse Biomedical
Impulse Biomedical is a company based in Cape Town (South Africa) founded in 2018. Impulse Biomedical offers products and services including Easy Squeezy and ZiBiPen. Impulse Biomedical operates in a competitive market with competitors including SetPoint Medical, Boomerang Medical, Hippo Dx, Therakos and Labseed, among others.
- Headquarter Cape Town, South Africa
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website impulsebiomed.com
- Social LinkedIn X Facebook YouTube
- Legal Name Impulse Biomedical
- Investors
Products & Services of Impulse Biomedical
Impulse Biomedical offers a comprehensive portfolio of products and services, including Easy Squeezy and ZiBiPen.
Asthma pump for easy medication delivery to patients.
Innovative device for enhanced medical treatment access.
Apps and channels of Impulse Biomedical
its YouTube channel Impulse Biomedical has 10 subscribers.
Funding Insights of Impulse Biomedical
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Impulse Biomedical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | – | Seed | – | Futuregrowth | – |
1 investors in total: 1 institutional.
Investors in Impulse Biomedical
Impulse Biomedical has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Futuregrowth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investment management firm | 1994 | futuregrowth.co.za | Cape Town, South Africa |
Investor details for Impulse Biomedical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Impulse Biomedical
2 dated milestones of Impulse Biomedical across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Impulse Biomedical is founded.
- Funding First funding round.
Competitors of Impulse Biomedical
Impulse Biomedical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SetPoint Medical, Boomerang Medical, Hippo Dx, Therakos and Labseed, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| setpointmedical.com | 2006 | Santa Clarita, United States | $363.17M | 46 | Implantable neuromodulation devices are developed for inflammatory diseases. | |
| boomerangmedical.com | 2021 | Mountain View, United States | $35M | – | Bioelectronic devices are developed for autoimmune disease treatment. | |
| hippo-dx.com | 2020 | Belgium | $4.67M | 6 | Developer of a medical device to provide an automated test that detects allergies | |
| therakos.com | 1984 | West Chester, United States | – | – | Therakos is focused on photopheresis systems for CTCL treatment. | |
| labseed.ch | 2009 | Lausanne, Switzerland | $115,346 | – | Technology to suppress capsular contraction is developed. | |
| theralight.com | 1999 | Lindon, United States | – | – | Provides red light therapy beds to promote cellular health and reduce oxidative stress. | |
| surftherapeutics.tcc.mode | 2022 | Austin, United States | – | – | Neuromodulatory technology for autoimmune disorder treatments is developed. | |
| airsonett.eu | 2000 | Angelholm, Sweden | – | – | Airsonett is focused on treating allergic asthma and dermatitis. |
Detailed competitors of Impulse Biomedical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Impulse Biomedical
The website of Impulse Biomedical (impulsebiomed.com) receives about 13.5K visits a month.
- Monthly visits13.5K
▲ 210.6% vs previous month
Latest news on Impulse Biomedical
Complete news archive for Impulse Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Impulse Biomedical
10 companies that operate in the same segment as Impulse Biomedical (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Impulse Biomedical
Impulse Biomedical was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Impulse Biomedical is headquartered in Cape Town, South Africa. It is registered at Cape Town, Western Cape, South Africa.
Impulse Biomedical was founded in 2018 in Cape Town, South Africa, and operates within the biomedical sector. Medical devices are developed, including the ZiBiPen, which administers adrenaline via a reloadable cartridge to address life-threatening anaphylaxis. A Frugal Biodesign platform has also been created to support efficient medical device design processes. Operations focus on innovation in allergy treatment solutions.
Impulse Biomedical's top competitors include SetPoint Medical, Boomerang Medical and Therakos.
Impulse Biomedical offers Easy Squeezy and ZiBiPen.
Impulse Biomedical has 1 investor. Key investors include Futuregrowth.
Impulse Biomedical operates through Impulse Biomedical.